NMRA
Neumora Therapeutics, Inc. Common Stock NASDAQ Listed Sep 15, 2023$1.94
Mkt Cap $354.4M
52w Low $0.61
43.7% of range
52w High $3.65
50d MA $2.52
200d MA $2.20
P/E (TTM)
-1.7x
EV/EBITDA
-0.5x
P/B
3.8x
Debt/Equity
0.0x
ROE
-228.1%
P/FCF
-1.4x
RSI (14)
—
ATR (14)
—
Beta
3.12
50d MA
$2.52
200d MA
$2.20
Avg Volume
1.3M
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
490 Arsenal Way · Watertown, DE 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | BMO | -0.34 | -0.35 | -2.9% | 2.87 | +0.7% | -1.4% | -8.0% | -10.5% | -12.5% | -13.9% | — |
| Nov 6, 2025 | BMO | -0.34 | -0.35 | -2.9% | 2.58 | -3.1% | -0.8% | +8.9% | +6.6% | +10.9% | +4.3% | — |
| Aug 6, 2025 | BMO | -0.38 | -0.33 | +13.2% | 1.59 | +4.4% | +3.8% | -8.2% | -9.4% | -5.7% | -1.9% | — |
| May 12, 2025 | BMO | -0.40 | -0.42 | -5.0% | 0.69 | -0.2% | -1.9% | -11.2% | -3.9% | +1.3% | -0.3% | — |
| Mar 3, 2025 | BMO | -0.46 | -0.37 | +19.6% | 1.41 | -2.8% | +0.0% | +1.4% | +7.8% | +5.7% | -5.0% | — |
| Nov 12, 2024 | BMO | -0.38 | -0.45 | -18.4% | 11.31 | +1.5% | -4.7% | +3.4% | -4.2% | -13.0% | -12.8% | — |
| Aug 6, 2024 | BMO | -0.37 | -0.37 | +0.0% | 11.99 | -0.3% | -1.7% | -6.3% | -6.1% | -6.9% | -5.8% | — |
| May 7, 2024 | BMO | -0.35 | -0.34 | +2.9% | 9.81 | -2.1% | -4.0% | -0.4% | -6.3% | -8.7% | -2.3% | — |
| Mar 7, 2024 | BMO | -0.65 | -0.71 | -9.2% | 19.00 | +3.3% | -5.3% | -5.0% | -8.7% | -22.1% | -20.4% | — |
| Nov 1, 2023 | BMO | -0.36 | -1.14 | -216.7% | 10.79 | -0.4% | +1.2% | +9.8% | +5.7% | +7.5% | -1.5% | — |
| Jun 30, 2023 | BMO | — | -0.25 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | BMO | — | -0.23 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 | Guggenheim | Maintains | Buy → Buy | — | $1.93 | $1.91 | -1.0% | +1.0% | +8.3% | +3.6% | +9.8% | +10.4% |
| Mar 31 | Needham | Maintains | Buy → Buy | — | $1.93 | $1.91 | -1.0% | +1.0% | +8.3% | +3.6% | +9.8% | +10.4% |
| Feb 17 | William Blair | Upgrade | Market Perform → Outperform | — | $3.20 | $3.35 | +4.7% | +10.6% | +12.2% | +8.8% | +5.9% | +7.8% |
| Dec 1 | RBC Capital | Upgrade | Sector Perform → Outperform | — | $2.24 | $2.53 | +12.9% | +8.0% | -0.4% | +1.3% | +1.8% | -0.9% |
| Nov 17 | Stifel | Maintains | Hold → Hold | — | $2.65 | $2.62 | -1.1% | -2.3% | +0.4% | -4.2% | -10.9% | -12.1% |
| Oct 28 | Needham | Maintains | Buy → Buy | — | $2.69 | $2.70 | +0.4% | -3.7% | -7.1% | +8.9% | +12.3% | +11.9% |
| Oct 27 | Guggenheim | Upgrade | Neutral → Buy | — | $2.63 | $2.68 | +1.9% | +2.3% | -1.5% | -4.9% | +11.4% | +14.8% |
| Sep 16 | JP Morgan | Downgrade | Neutral → Underweight | — | $1.52 | $1.50 | -1.3% | -1.3% | -4.6% | +3.3% | +15.8% | +13.8% |
| Jul 16 | Mizuho | Maintains | Outperform → Outperform | — | $1.45 | $1.53 | +5.5% | -3.4% | +17.9% | +27.6% | +35.2% | +30.3% |
| May 13 | Needham | Maintains | Buy → Buy | — | $0.69 | $0.69 | -0.2% | -1.9% | -11.2% | -3.9% | +1.3% | -0.3% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $0.76 | $0.72 | -4.7% | -5.2% | -9.8% | -11.4% | -13.2% | -16.6% |
| Apr 2 | BofA Securities | Downgrade | Buy → Underperform | — | $0.91 | $0.89 | -2.6% | +3.0% | -7.0% | -19.4% | -17.5% | -20.8% |
| Mar 10 | Guggenheim | Downgrade | Buy → Neutral | — | $1.49 | $1.43 | -4.0% | -10.1% | -4.0% | -7.4% | -6.0% | -14.1% |
| Mar 7 | Stifel | Downgrade | Buy → Hold | — | $1.52 | $1.32 | -13.2% | -2.0% | -11.8% | -5.9% | -9.2% | -7.9% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.32 | -13.2% | -2.0% | -11.8% | -5.9% | -9.2% | -7.9% |
| Mar 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $1.41 | $1.37 | -2.8% | +0.0% | +1.4% | +7.8% | +5.7% | -5.0% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.41 | $1.37 | -2.8% | +0.0% | +1.4% | +7.8% | +5.7% | -5.0% |
| Mar 4 | Needham | Maintains | Buy → Buy | — | $1.41 | $1.37 | -2.8% | +0.0% | +1.4% | +7.8% | +5.7% | -5.0% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.69 | $1.72 | +1.8% | +3.0% | +2.4% | -1.8% | +1.2% | +6.5% |
| Jan 6 | BofA Securities | Maintains | Buy → Buy | — | $2.17 | $2.24 | +3.2% | +14.3% | +18.9% | +9.2% | +1.8% | +11.5% |
| Jan 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.97 | $2.23 | +13.2% | +10.2% | +25.9% | +31.0% | +20.3% | +12.2% |
| Jan 2 | Needham | Maintains | Buy → Buy | — | $10.60 | $1.88 | -82.3% | -81.4% | -79.5% | -76.6% | -75.7% | -77.6% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.32 | $10.40 | +0.8% | +5.3% | +5.3% | -1.4% | +1.7% | +5.1% |
| Nov 22 | RBC Capital | Maintains | Outperform → Outperform | — | $9.69 | $9.79 | +1.0% | +0.5% | -0.2% | +0.8% | +0.7% | +2.6% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $11.31 | $11.48 | +1.5% | -4.7% | +3.4% | -4.2% | -13.0% | -12.8% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.31 | $11.48 | +1.5% | -4.7% | +3.4% | -4.2% | -13.0% | -12.8% |
| Nov 5 | JP Morgan | Downgrade | Overweight → Neutral | — | $11.71 | $11.02 | -5.9% | +1.7% | +8.5% | +11.2% | +15.6% | +16.5% |
| Oct 18 | Needham | Maintains | Buy → Buy | — | $16.96 | $17.00 | +0.2% | -2.8% | -17.2% | -17.7% | -21.5% | -23.3% |
| Sep 12 | Needham | Maintains | Buy → Buy | — | $11.40 | $11.50 | +0.9% | +3.8% | +5.5% | +4.7% | +2.9% | +7.1% |
| Sep 4 | RBC Capital | Maintains | Outperform → Outperform | — | $10.74 | $10.74 | +0.0% | +2.3% | +0.5% | -2.6% | +6.2% | +5.1% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $11.99 | $11.95 | -0.3% | -1.7% | -6.3% | -6.1% | -6.9% | -5.8% |
| Mar 28 | RBC Capital | Maintains | Outperform → Outperform | — | $12.61 | $12.98 | +2.9% | +9.0% | +10.5% | +9.2% | +5.5% | +8.9% |
| Mar 18 | JP Morgan | Maintains | Overweight → Overweight | — | $15.09 | $14.98 | -0.7% | -6.2% | -7.0% | -7.3% | -7.4% | -12.5% |
| Mar 8 | RBC Capital | Maintains | Outperform → Outperform | — | $19.00 | $19.63 | +3.3% | -5.3% | -5.0% | -8.7% | -22.1% | -20.4% |
| Nov 8 | JP Morgan | Maintains | Overweight → Overweight | — | $11.60 | $12.09 | +4.2% | -8.4% | -8.6% | -0.2% | +3.1% | +2.2% |
No insider trades available.
8-K · 2.02
!! High
Neumora Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Neumora Therapeutics reported Q1 2026 financial results, providing investors with updated operational metrics and financial performance for the quarter ending March 31, 2026.
May 7
8-K
Unknown — 8-K Filing
Neumora's clinical-stage pipeline and cash position updates will clarify runway for drug development and whether the company can reach key milestones before requiring additional financing, directly impacting dilution risk.
Mar 30
8-K · 7.01
! Medium
Neumora Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Neumora Therapeutics (NMRA) disclosed a presentation through Regulation FD, providing investors with updated information about the company's business and strategy.
Feb 11
Data updated apr 26, 2026 3:20pm
· Source: massive.com